COMP <GO>
ARDX vs UNH // ENTERPRISE SCALE & MARKET CAP
Ardelyx Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ARDX 2
— UNH 9
▲ ENTERPRISE SCALE & MARKET CAP LEADER: UNH
LAST: $3.03 (0.00%) • MKT CAP: $755.0M
market-cap
$755.0M
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
market-cap
$359.43B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARDX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARDX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 90.30% | 88.31% | +1.99 | ARDX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.70% | 12.38% | -45.08 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.69% | 6.25% | -11.94 | UNH | /fcf-yield <GO> |
| Operating Margin | -10.10% | 5.32% | -15.42 | UNH | /operating-margins <GO> |
| Net Profit Margin | -15.20% | 3.53% | -18.73 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 22.10% | 3.33% | +18.77 | ARDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 3.09 | -2.89 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.9 | 55.1 | -16.20 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $755.0M | $359.43B | -$358.68B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARDX REV | UNH REV | ARDX GROSS % | UNH GROSS % | ARDX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $407.3M | $447.57B | 90.3% | 88.7% | -$44.0M | $16.07B |
| FY 2024 | $333.6M | $400.28B | 84.8% | 88.3% | -$45.8M | $20.70B |
| FY 2023 | $124.5M | $371.62B | — | 89.6% | -$89.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARDX // BETA —
UNH // BETA 0.33